OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN:…
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in Phase 2 study of…
July 01, 2025 09:00 ET | Source: Inmagene Biopharmaceuticals The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007…
ESTERO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Visory Health, a leading patient-first health tech prescription platform that is transforming…
Novonesis has now completed the announced share buyback program of B shares worth up to EUR 100 million (DKK 746…
OSE Immunotherapeutics Publishes Letter to Shareholders NANTES, France, June 30, 2025, 6:00 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:…
June 30, 2025 12:00 ET | Source: IBA SA June 30th, 2025 Publication made under article 15 of the…
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches…
TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today the voting results…
Hapbee Expands Board by Three Members with Senior Leaders in Tech, Legal, and Finance as it Enters Next Phase of…